Close
Baker Young Corporate provides strategic corporate advisory and equity capital markets services to ASX-listed and private companies seeking growth capital, market expertise, and transaction execution support.
Our team has extensive experience advising emerging and established businesses across a broad range of industries, delivering tailored solutions across capital markets, strategic transactions, and corporate growth initiatives.
We combine commercial insight, transaction experience, and strong institutional and retail market relationships to help businesses achieve their strategic objectives and access capital efficiently.
| Date / Period | Company | ASX | Baker Young Role | Transaction Type |
| FY2024/25 | Neuphoria Therapeutics / Bionomics | NEUP / BNOX | Sale Agent | Voluntary Sale Facility associated with re-domiciliation |
| FY2024/25 | Koonenberry Gold | KNB | Joint Lead Manager, Joint Lead Broker & Joint Underwriter | Fully underwritten Entitlement Offer |
| FY2023/24 | Novatti Group | NOV | Joint Lead Manager | Convertible note facility + SPP |
| FY2023/24 | Hydrix | HYD | Lead Manager | Convertible note raising |
| FY2023/24 | NuEnergy Gas | NGY | Nominee / Broker / Rights Offer Participant | Non-renounceable Entitlement Offer |
| FY2023/24 | Paradigm Biopharmaceuticals | PAR | Broker / Execution Support | On-market buy-back support & capital markets activity |
| FY2021/22 | Radiopharm Theranostics | RAD | Joint Lead Manager | IPO |
| FY2021/22 | Arovella Therapeutics | ALA | Underwriter | Share Purchase Plan |
| FY2020/21 | Chimeric Therapeutics | CHM | Joint Lead Manager | IPO |
| FY2020/21 | Global Health | GLH | Joint Lead Manager | Placement |
| FY2020/21 | Nutritional Growth Solutions | NGS | Joint Lead Manager | IPO |
| FY2020/21 | Mt Monger Resources / Metallium | MTM | Joint Lead Manager | IPO |
| FY2020/21 | Delta Drone International | DLT | Corporate Advisory / Lead Manager | IPO / RTO |
| FY2020/21 | Chimeric Therapeutics | CHM | Lead Manager | Pre-IPO |
| FY2020/21 | Pan Asia Metals | PAM | Lead / Joint Lead Manager | IPO |
| FY2020/21 | SUDA Pharmaceuticals | SUD | Lead Broker | Placement + Entitlement Offer |
| FY2020/21 | SUDA Pharmaceuticals | SUD | Lead Broker | Placement |
| FY2020/21 | Novatti Group | NOV | Lead Manager | Convertible Notes |
| FY2020/21 | SUDA Pharmaceuticals | SUD | Lead Broker | Placement |
| FY2020/21 | Whitebark Energy | WBE | Joint Lead Manager & Underwriter | Entitlement Offer |
| FY2020/21 | Gladiator Resources | GLA | Lead Manager & Underwriter | Rights Issue / Placement |
| FY2020/21 | Mayfield Group Holdings | MYG | Corporate Advisory / Lead Manager | IPO |
| FY2020/21 | Gladiator Resources | GLA | Lead Manager | Placement |
| FY2020/21 | Mt Monger Resources / Metallium | MTM | Joint Lead Manager | Pre-IPO |
| FY2020/21 | 3D Resources | DDD | Lead Broker | Option Shortfall Placement / Underwriting Support |
| FY2019/20 | Alexium International Group | AJX | Lead Broker | Accelerated Entitlement Offer + Placement |
| FY2019/20 | Noxopharm | NOX | Lead Broker | Placement |
| FY2019/20 | NuEnergy Gas | NGY | Nominee / Broker | Entitlement Offer |
| FY2019/20 | Paradigm Biopharmaceuticals | PAR | Broker / Investor Introductions | Placement |
| FY2019/20 | Rotogro International | RGI | Lead Broker | Placement |
| FY2019/20 | 3D Resources | DDD | Lead Broker | Placement |
| FY2019/20 | Paterson Resources | PSL | Lead Broker | Entitlement Offer + Shortfall Placement |
Decades of market experience combined with a truly personalised approach. Trusted advice focused on long term relationships and consistent results.
01
Decades of proven experience guiding investors through every market cycle.
02
Access to opportunities across global and local markets.
03
Transparent, fair pricing designed to deliver value without compromise.
Your journey begins with a conversation about your long-term goals. We handle the rest with a structured and seamless onboarding process.